A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials

Haematologica. 2022 Aug 1;107(8):1960-1965. doi: 10.3324/haematol.2022.280629.
No abstract available

MeSH terms

  • B-Cell Maturation Antigen
  • Cell- and Tissue-Based Therapy
  • Clinical Trials, Phase I as Topic
  • Humans
  • Immunotherapy, Adoptive / methods
  • Multiple Myeloma* / therapy
  • Neoplasms, Plasma Cell*
  • Receptors, Chimeric Antigen* / genetics

Substances

  • B-Cell Maturation Antigen
  • Receptors, Chimeric Antigen

Grants and funding

Funding: This work was supported by a grant from the Shanghai Strategic Emerging Industry Development Foundation and by CARsgen Therapeutics.